Home › Funds › SR ONE CAPITAL MANAGEMENT, LP › AVLN
SR ONE CAPITAL MANAGEMENT, LP position in AVLN
AVALYN PHARMACEUTICALS INC · Health Care
SR ONE CAPITAL MANAGEMENT, LP reported holding 3,308,649 shares of AVLN (AVALYN PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$94.3M, representing 8.20% of its reported portfolio and ranking #5 among its reported holdings. SR ONE CAPITAL MANAGEMENT, LP has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How SR ONE CAPITAL MANAGEMENT, LP's AVLN position evolved
SR ONE CAPITAL MANAGEMENT, LP first disclosed a stake in AVLN in Q2 2026 at 3,308,649 shares (US$108.9M). Across 2 filings, SR ONE CAPITAL MANAGEMENT, LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 3,308,649 shares valued at US$94.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 3.31M | $108.92M | New |
| Q3 2026 | 3.31M | $94.26M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVLN and 13F data
AVLN (AVALYN PHARMACEUTICALS INC) is a Health Care company. 114 other funds we track also report a position in AVLN — the largest reported positions include Novo Holdings A/S (US$98.3M), PERCEPTIVE ADVISORS LLC (US$76.2M), MONTANOVA CAPITAL, LLC (US$71.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVLN
- Novo Holdings A/S 3.45M sh · $98.27M · Q3 2026
- PERCEPTIVE ADVISORS LLC 2.68M sh · $76.22M · Q3 2026
- MONTANOVA CAPITAL, LLC 2.50M sh · $71.31M · Q3 2026
- NVP Associates, LLC 2.27M sh · $64.63M · Q3 2026
- Catalio Capital Management, LP 1.70M sh · $48.40M · Q3 2026
- Bellevue Group AG 1.35M sh · $38.46M · Q3 2026
- Soleus Capital Management, L.P. 1.02M sh · $29.03M · Q3 2026
- Andera Partners 929.82K sh · $26.49M · Q3 2026
- Pivotal bioVenture Partners Investment Advisor LLC 866.79K sh · $24.69M · Q3 2026
- TPG GP A, LLC 773.07K sh · $22.02M · Q3 2026
- BRAIDWELL LP 744.46K sh · $21.21M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 731.00K sh · $20.83M · Q3 2026
More on SR ONE CAPITAL MANAGEMENT, LP
FAQ
How long has SR ONE CAPITAL MANAGEMENT, LP held AVLN?
SR ONE CAPITAL MANAGEMENT, LP has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is SR ONE CAPITAL MANAGEMENT, LP's current position in AVLN?
As of Q3 2026, SR ONE CAPITAL MANAGEMENT, LP holds 3.31M shares of AVLN (AVALYN PHARMACEUTICALS INC), valued at $94.26M, representing 8.20% of its reported portfolio and ranking #5.
Has SR ONE CAPITAL MANAGEMENT, LP been buying or selling AVLN?
In the latest 13F filing (Q3 2026), SR ONE CAPITAL MANAGEMENT, LP held unchanged its position in AVLN.
Which other funds hold AVLN?
Other major institutional holders of AVLN include Novo Holdings A/S, PERCEPTIVE ADVISORS LLC, MONTANOVA CAPITAL, LLC, among 114 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.